NCT06133712 Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief
| NCT ID | NCT06133712 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Carpal Tunnel |
| Study Type | INTERVENTIONAL |
| Enrollment | 135 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 135 participants in total. It began in 2023-11-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the present study is to compare the analgesic efficacy of Dexmedetomidine, Ozone and Dexamethasone regional injection in carpal tunnel syndrome.
Eligibility Criteria
Inclusion Criteria: * Age from 20 to 60 years. * Both sexes. * Patients with ultrasonographic evidence of mild-to-moderate carpal tunnel syndrome (CTS). * Inclusion criteria will include numbness and pain in the median nerve (MN) distribution persisting for minimum of 3 months , nerve conduction studies (NCS) consistent with carpal tunnel syndrome (CTS) as per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines, and an median nerve (MN) cross-sectional area (CSA)at the wrist \>12 mm2 suggesting mild-to-moderate CTS forms. Exclusion Criteria: * Patient refusal. * Patients with severe symptoms and signs of CTS as identified per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines,\[14\] as this is an indication for surgery, * Patients who show improvement on medical treatment, * Previous surgical or injectional CTS treatment, * Pregnancy ,co existence of brachial plexopathy, or thoracic outlet syndrome, polyneuropathy, radiculopathy and peripheral nerve lesion in upper limb. * Severe cardiovascular disease * Morbid obese patients (body mass index (BMI) of \>35 kg/m2) * Infection at site of injection. * Bleeding diathesis. * History of thyroid deficiency, uncontrolled diabetes mellitus , rheumatoid arthritis and history of glucose-6-phosphate dehydrogenase (G6PD) deficiency * History of Ozone or Dexmedetomidine allergy. * End stage renal and hepatic disease. * History of inflammatory joint , connective tissue disorders, , burns, any local tissue contractures and history of wrist trauma. * Patients who will not consent to completing The visual analogue scale (VAS) for pain or nerve conduction study before and after injection.
Contact & Investigator
MAHMOUD ELGEBALY, MD
PRINCIPAL INVESTIGATOR
Tanta faculty of medicine
Frequently Asked Questions
Who can join the NCT06133712 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Carpal Tunnel. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06133712 currently recruiting?
Yes, NCT06133712 is actively recruiting participants. Contact the research team at mahmoud.talaat@med.tanta.edu for enrollment information.
Where is the NCT06133712 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06133712 clinical trial?
NCT06133712 is sponsored by Tanta University. The principal investigator is MAHMOUD ELGEBALY, MD at Tanta faculty of medicine. The trial plans to enroll 135 participants.